NCT01110499 - Safety and Efficacy of AGN-210961 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension | Biotech Hunter

Enrollment

163

Participants

Timeline

Start Date

June 30, 2010

Primary Completion Date

May 31, 2011

Study Completion Date

June 30, 2011

Conditions

Ocular HypertensionPrimary Open-Angle Glaucoma

Interventions

DRUG

AGN-210961 Formulation 1

AGN-210961 Formulation 1 in one eye once daily for 7 days.

DRUG

AGN-210961 Formulation 2

AGN-210961 Formulation 2 in one eye once daily for 7 days.

DRUG

AGN-210961 Formulation 3

AGN-210961 Formulation 3 in one eye once daily for 7 days.

DRUG

AGN-210961 Formulation 4

AGN-210961 Formulation 4 in one eye once daily for 7 days.

DRUG

AGN-210961 Formulation 5

AGN-210961 Formulation 5 in one eye once daily for 7 days.

DRUG

AGN-210961 Formulation 6

AGN-210961 Formulation 6 in one eye once daily for 7 days.

DRUG

AGN-210961 Formulation 7

AGN-210961 Formulation 7 in both eyes once daily for 4 weeks.

DRUG

bimatoprost ophthalmic solution 0.03%

bimatoprost ophthalmic solution 0.03% (LUMIGAN®) in both eyes once daily for 4 weeks.

Trial Locations (1)

Newport Beach